| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA236: Ticagrelor for the treatment of acute coronary syndromes. |
|
Medicine details |
|
| Medicine name | ticagrelor (Brilique®) |
| Formulation | 90 mg film-coated tablet |
| Reference number | 391 |
| Indication | Co-administered with acetylsalicylic acid for the prevention of atherothrombotic events in adult patients with acute coronary syndromes (unstable angina, non ST elevation myocardial infarction [NSTEMI] or ST elevation myocardial infarction [STEMI]); including patients managed medically, and those who are managed with percutaneous coronary intervention (PCI) or coronary artery by-pass grafting (CABG) |
| Company | AstraZeneca UK Ltd |
| BNF chapter | Cardiovascular system |
| Assessment type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 10/01/2011 |
| NICE guidance | TA236: Ticagrelor for the treatment of acute coronary syndromes |